NASDAQ$CRSP
CRISPR Therapeutics AG · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
CRISPR Therapeutics reported financial results for the first quarter ended March 31, 2020.
CRISPR Therapeutics reported a net loss of $69.7 million for the first quarter of 2020, with cash and cash equivalents totaling $889.7 million. The company is progressing five cell therapy clinical trials and expects to report data for CTX001 and CTX110 programs this year. A $25 million milestone payment was received from Vertex in April 2020 related to the DM1 program.
- Enrollment is ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies.
- Enrollment is ongoing in clinical trial of CTX110, targeting CD19+ malignancies.
- Patient treatment has begun in the clinical trial of CTX120, targeting B-cell maturation antigen (BCMA).
- IND and CTA were approved for CTX130, a wholly-owned allogeneic CAR-T cell therapy targeting CD70.
Headline financials
Revenue & EPS history
CRISPR Therapeutics · Revenue · Quarterly
$157K
Revenue by segment
CRISPR Therapeutics · $762K total across 1 segment · Q1 2022
- Grant Revenue$762K+126.1%100.0%
Forward guidance
CRISPR Therapeutics is focused on advancing its clinical programs, including CTX001, CTX110, CTX120, and CTX130. The company expects to report data from CTX001 and CTX110 programs in 2020 and begin treating patients with CTX130 in the second half of the year.
Tailwinds
- Remain on track to provide additional data from the two ongoing Phase 1/2 studies of CTX001 in patients with transfusion-dependent beta thalassemia and in patients with severe sickle cell disease in 2020.
- Expect to report top-line data for CTX110 at the end of 2020.
- Have begun treating patients in a clinical trial to assess the safety and efficacy of CTX120.
- Expect to begin treating patients with CTX130 in the second half of this year.
- Eligible to receive additional milestone payments from Vertex of up to $800 million for DMD and DM1 programs.
Headwinds
- No additional patients are scheduled to initiate conditioning or dosing at this time due to COVID-19.
- Potential impacts due to the coronavirus pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy.
- The timing and progress of clinical trials, preclinical studies and other research and development activities may be affected by the coronavirus pandemic.
- The overall impact of the coronavirus pandemic on its business, financial condition and results of operations is uncertain.
- The potential for initial and preliminary data from any clinical trial not to be indicative of final trial results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+2.1%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
19 / 40 earnings
Positive
+22.8%
Q3 2019
Best reaction
-7.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +2.4% | +6.3% | |
| Q4 2025 | +1.2% | +10.0% | +0.9% | |
| Q3 2025 | -1.0% | -4.7% | +4.5% | |
| Q1 2025 | -0.1% | -3.2% | +7.2% | |
| Q4 2024 | -2.8% | -8.3% | -18.2% | |
| Q3 2024 | +0.3% | +2.0% | -2.1% | |
| Q2 2024 | -3.5% | -8.0% | -11.9% | |
| Q1 2024 | -3.6% | +0.2% | +4.2% | |
| Q4 2023 | +9.5% | +9.3% | -9.0% | |
| Q3 2023 | +14.9% | +4.3% | +39.5% | |
| Q2 2023 | +4.1% | -2.6% | +0.3% | |
| Q1 2023 | +13.7% | +14.5% | +12.5% | |
| Q4 2022 | -1.0% | -5.6% | -15.2% | |
| Q3 2022 | +4.5% | -2.2% | +3.8% | |
| Q2 2022 | -7.7% | -3.4% | -20.1% | |
| Q1 2022 | -1.5% | +8.8% | +53.8% | |
| Q4 2021 | +5.7% | -0.5% | +15.1% | |
| Q3 2021 | -3.0% | -1.8% | -26.9% | |
| Q2 2021 | +1.1% | +1.4% | +3.4% | |
| Q1 2021 | -0.1% | -3.3% | -12.8% | |
| Q4 2020 | -6.8% | -7.5% | -23.3% | |
| Q3 2020 | -1.8% | -12.2% | +23.9% | |
| Q2 2020 | -4.4% | -5.4% | -1.6% | |
| Q1 2020 | -5.5% | -11.9% | +13.3% | |
| Q4 2019 | +2.0% | -2.1% | -34.0% | |
| Q3 2019 | +22.8% | +27.7% | +70.9% | |
| Q2 2019 | -2.3% | -3.9% | -11.2% | |
| Q1 2019 | -2.0% | -1.1% | -10.1% | |
| Q4 2018 | +14.3% | +26.2% | +8.0% | |
| Q3 2018 | +7.5% | +3.2% | +0.0% | |
| Q2 2018 | -2.7% | -2.7% | +3.0% | |
| Q1 2018 | -0.4% | +2.0% | +29.6% | |
| Q4 2017 | +10.2% | +9.7% | -16.0% | |
| Q3 2017 | -6.5% | -2.1% | +4.1% | |
| Q2 2016 | +9.4% | +10.1% | +6.7% | |
| Q2 2017 | +9.4% | +10.1% | +6.7% | |
| Q1 2016 | -0.1% | -2.9% | -14.2% | |
| Q1 2017 | +4.3% | -4.2% | -17.9% | |
| Q4 2016 | +11.1% | +13.3% | -12.4% | |
| Q3 2016 | -7.0% | -1.9% | -3.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro